Brokerages Set Sanofi (NASDAQ:SNY) Target Price at $62.67

Sanofi (NASDAQ:SNY) has been given a consensus rating of “Moderate Buy” by the fourteen ratings firms that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $62.6667.

SNY has been the subject of several analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. Barclays cut Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Friday. Finally, HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th.

Hedge Funds Weigh In On Sanofi

A number of institutional investors have recently added to or reduced their stakes in the stock. Perigon Wealth Management LLC boosted its position in Sanofi by 12.2% in the fourth quarter. Perigon Wealth Management LLC now owns 6,172 shares of the company’s stock valued at $299,000 after buying an additional 671 shares in the last quarter. Aberdeen Group plc lifted its stake in shares of Sanofi by 22.7% in the 4th quarter. Aberdeen Group plc now owns 467,241 shares of the company’s stock valued at $22,642,000 after acquiring an additional 86,314 shares during the last quarter. HF Advisory Group LLC boosted its holdings in shares of Sanofi by 131.5% during the 4th quarter. HF Advisory Group LLC now owns 71,708 shares of the company’s stock valued at $3,475,000 after acquiring an additional 40,738 shares in the last quarter. Legacy Capital Wealth Partners LLC grew its position in Sanofi by 3.5% during the 4th quarter. Legacy Capital Wealth Partners LLC now owns 12,354 shares of the company’s stock worth $599,000 after acquiring an additional 420 shares during the last quarter. Finally, Frank Rimerman Advisors LLC acquired a new position in Sanofi in the 4th quarter worth about $497,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $46.59 on Thursday. The business has a fifty day moving average price of $48.92 and a two-hundred day moving average price of $48.82. The stock has a market capitalization of $113.63 billion, a PE ratio of 10.91, a P/E/G ratio of 1.16 and a beta of 0.45. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.30. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 24th. The company reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company had revenue of $15.46 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter last year, the business earned $2.25 earnings per share. Sanofi’s revenue was down 7.5% on a year-over-year basis. As a group, equities analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.